Matthew Sykes
Stock Analyst at Goldman Sachs
(4.10)
# 480
Out of 5,129 analysts
210
Total ratings
55.1%
Success rate
11.15%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $11.59 | -56.86% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.36 | -31.19% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $19.15 | -66.06% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $42.43 | +6.06% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.85 | +64.95% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $49.64 | -3.30% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $17.37 | -2.13% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $133.14 | +20.17% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $11.45 | -12.66% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $101.10 | +23.64% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $9.64 | +45.23% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $219.98 | +9.10% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $19.71 | +31.91% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $165.98 | +2.42% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $107.58 | -47.95% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $91.44 | -12.51% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.84 | -18.48% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $212.46 | -10.57% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.16 | -18.98% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.12 | +36.22% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $35.99 | +2.81% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $103.43 | -37.16% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $177.18 | +41.10% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.99 | +300.67% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,392.65 | -6.65% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $9.35 | +28.34% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $527.17 | +21.40% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $128.90 | +12.49% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $51.06 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $11.59
Upside: -56.86%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.36
Upside: -31.19%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $19.15
Upside: -66.06%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $42.43
Upside: +6.06%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.85
Upside: +64.95%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $49.64
Upside: -3.30%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $17.37
Upside: -2.13%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $133.14
Upside: +20.17%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $11.45
Upside: -12.66%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $101.10
Upside: +23.64%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $9.64
Upside: +45.23%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $219.98
Upside: +9.10%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $19.71
Upside: +31.91%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $165.98
Upside: +2.42%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $107.58
Upside: -47.95%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $91.44
Upside: -12.51%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.84
Upside: -18.48%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $212.46
Upside: -10.57%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.16
Upside: -18.98%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.12
Upside: +36.22%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $35.99
Upside: +2.81%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $103.43
Upside: -37.16%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $177.18
Upside: +41.10%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.99
Upside: +300.67%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,392.65
Upside: -6.65%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $9.35
Upside: +28.34%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $527.17
Upside: +21.40%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $128.90
Upside: +12.49%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $51.06
Upside: -